Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Endometrial Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Prostatic Neoplasms 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Urinary Bladder Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Colonic Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Retinoblastoma 1Peritoneal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroblastoma 1Neoplasms 1Mouth Neoplasms 1

Interventions

Mitomycin 5Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Fluorouracil 4Capecitabine 4Biopsy 4pembrolizumab 3Drug Therapy 3dehydroftorafur 2Vaccines 2Sigmoidoscopy 2Radiotherapy, Intensity-Modulated 2Radiation 2Proctoscopy 2Mitozytrex 2Fluorodeoxyglucose F18 2Colonoscopy 2tislelizumab 1spartalizumab 1entinostat 1durvalumab 1bintrafusp alfa protein, human 1X-Rays 1Watchful Waiting 1Vaccines, Synthetic 1Tomography, X-Ray Computed 1Taxes 1Surveys and Questionnaires 1Sentinel Lymph Node Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Anus Neoplasms × Observation × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡